Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

Arthritis and Rheumatism

Volumn 52, Issue 3, 2005, Pages 818-825

  Yokota, Shumpei ^a   Miyamae, Takako ^a   Imagawa, Tomoyuki ^a   Iwata, Naomi ^a   Katakura, Shigeki ^a   Mori, Masaaki ^a   Woo, Patricia ^b   Nishimoto, Norihiro ^c   Yoshizaki, Kazuyuki ^c   Kishimoto, Tadamitsu ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Windeyer Institute of Medical Sciences   (United Kingdom)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CORTICOSTEROID; HUMANIZED RECOMBINANT INTERLEUKIN 6 RECEPTOR ANTIBODY; INTERLEUKIN 6; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECZEMA; FEMALE; GLUCOSURIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGAMMAGLOBULINEMIA; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LONG TERM CARE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PUSTULE; SCHOOL CHILD; SIDE EFFECT; SYSTEMIC DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ACUTE-PHASE PROTEINS; ADOLESCENT; ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MALE; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 20144362101     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20944     Document Type: Article

References (23)

1. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25:1991-4.
2. Cassidy JT, Petty RE. Textbook of pediatric rheumatology. 4th ed. Philadelphia: W. B. Saunders; 2001.
3. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985;106: 561-6.
4. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
5. Packham JC, Hall MA, Pimm TJ. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: predictive factors for mood and pain. Rheumatology (Oxford) 2002;41:1444-9.
6. Zak M, Muller J, Karup Pedersen F. Final height, armspan, subischial leg length and body proportions in juvenile chronic arthritis: a long-term follow-up study. Horm Res 1999;52:80-5.
7. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25: 203-7.
8. Rooney M, David J, Symons J, di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-60.
9. De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114-9.
10. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95: 56-61.
11. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002;46:3388-9.
12. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46: 3143-50.
13. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis: phase I/II clinical study. J Rheumatol 2003;30:1426-35.
14. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993;53: 851-6.
15. Ledur A, Fitting C, David B, Hamberger C, Cavaillon JM. Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. J Immunol Methods 1995;186:171-9.
16. Novick D, Engelmann H, Revel M, Leitner O, Rubinstein M. Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding. Hybridoma 1991;10:137-46.
17. Nugent J, Ruperto N, Grainger J, Machado C, Sawhney S, Baildam E, et al. The British version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19:S163-7.
18. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
19. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998;10: 729-34.
20. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A 1995;92:4862-6.
21. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
22. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59:i21-7.
23. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.